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Accepted 9 July 2013; Published online 25 September 2013AbstractObjectives: The Alzheimer’s Disease Assessment Scaleecognitive section and its standardized version (SADAS-cog) are the current
standard for assessing cognitive outcomes in clinical trials of dementia. This study compares a shorter cognitive instrument, the Quick Mild
Cognitive Impairment (Qmci) screen, with the SADAS-cog as outcome measures in clinical trials.
Study Design and Setting: The SADAS-cog, Qmci, Clinical Dementia Rating (CDR) scale, and the LawtoneBrady activities of daily
living (ADL) scale were assessed at multiple time points, over 1 year in a multicenter randomized clinical trial of 406 patients with mild to
moderate Alzheimer’s dementia. Correlations were estimated using regression at each time point, all time points, and mean values across
time. Responsiveness was assessed using the standardized response mean (SRM).
Results: Regression for pooled time points showed strong and significant correlation between the SADAS-cog and Qmci (r 5 0.75,
P! 0.001). Correlations remained strong for mean values across time and at each time point. The SADAS-cog and Qmci also correlated
with CDR and ADL scores. There was no difference in SRMs between the SADAS-cog and Qmci [t(357) 5 0.32, P 5 0.75].
Conclusion: The Qmci correlated strongly with the SADAS-cog and both were equally responsive to deterioration. We suggest that
clinicians and investigators can substitute the shorter Qmci for the SADAS-cog.  2014 The Authors. Published by Elsevier Inc.
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1. Introduction are established as the standard [1]. Several are limited by
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Open access under CCtheir inability to detect significant variations between pa-
tients with respect to age and/or educational status [2]. Re-
searchers and clinicians require short instruments that are
reliable, valid, and responsive to change across a wide range
of cognitive function. They needmultiple standardized scor-
ing formats that measure changes early (high ceiling) and in
the later stages of dementia (low floor).
The existing accepted standard for measuring cognitive
function in clinical trials in dementia is the Alzheimer’s Dis-
ease Assessment Scaleecognitive section (ADAS-cog)
[3e5]. TheADAS-cog has 11 domains, includingword recall,
object naming, command following, construction and idea-
tional praxis, orientation, word recognition, language, speech
comprehension, word finding and recall, and takes
30e40 minutes to complete [3]. Total scores range from 0 to
70; higher scores (18) indicate greater cognitive impairment.
The minimal important change has been determined to be BY-NC-ND license. 
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Key findings
 The Quick Mild Cognitive Impairment (Qmci)
screen correlates strongly and significantly to
the Standardized Alzheimer’s Disease Assessment
Scaleecognitive section (SADAS-cog) over time.
 The Qmci had moderate correlation with the Clin-
ical Dementia Rating scale and activities of daily
living.
What this adds to what was known?
 This study confirms that short screening tools can
be used instead of longer cognitive assessments
in clinical trials.
 The Qmci, specifically designed to identify mild
cognitive impairment, can be used to identify and
measure cognitive impairment in clinical trials, po-
tentially improving the ability to detect early cog-
nitive changes in clinical trials.
What is the implication and what should change
now?
 This study suggests that investigators could sub-
stitute the shorter Qmci for the SADAS-cog as a
cognitive outcome measure in clinical trials, partic-
ularly where differentiating mild cognitive im-
pairment from normal cognition and dementia is
important.
approximately four points and many regulatory authorities,
including the US Food and Drug Administration, require
evidence of such change at 6 months to confirm the benefit
of any new medication [6e8].
The ADAS-cog, although comprehensive and useful at
different stages of dementia, has limitations. The ADAS-
cog is long, requires training, and there is concern about
the instruments’ interrater reliability [9]. It also has a ceiling
effect, limiting usefulness in the initial stages of dementia
[10]. To overcome these limitations, the Standardized Alz-
heimer’s Disease Assessment Scaleecognitive section
(SADAS-cog) was developed, to improve interrater reliabil-
ity using explicit administration and scoring guidelines
[11]. The SADAS-cog is equally lengthy, taking up to
45 minutes.
1.1. The Quick Mild Cognitive Impairment screen
The Quick Mild Cognitive Impairment (Qmci) screen
was developed to screen for mild cognitive impairment
(MCI). The Qmci was refined from the AB Cognitive
Screen (ABCS 135) [12], by reweighting the originalsubtests and adding a logical memory section. It measures
cognition across a full range of cognition from normal cog-
nition (NC) to MCI and severe dementia. The Qmci has six
domains: orientation, registration, clock drawing, delayed
recall, verbal fluency, and logical memory scored as fol-
lows: orientation (10), registration (5), clock drawing
(15), registration (20), verbal fluency (20), and logical
memory (30). It takes 3e5 minutes to complete. The Qmci
is more sensitive and specific than the Standardized Mini-
Mental State Examination (SMMSE) [13,14] at differenti-
ating MCI from NC and dementia [12]. The Qmci is scored
out of 100, and depending on age and educational levels, 50
is the cutoff for dementia. The Qmci can be completed in
3e5 minutes, median time of 4.24 minutes [15].
1.2. The DARAD trial
The doxycycline and rifampicin for Alzheimer’s Disease
(DARAD) was a multicenter, blinded, randomized con-
trolled trial comparing two antibiotics, rifampicin and
doxycycline, with placebo to confirm if preliminary evi-
dence, suggesting that these antibiotics can delay the pro-
gression of Alzheimer’s disease [16], was correct [17].
Outcome measures included functional, mood, behavioral,
and two cognitive assessments, the SADAS-cog and Qmci.
We used data from the DARAD trial to compare the
Qmci and SADAS-cog to determine if the Qmci is an alter-
native to the SADAS-cog as an outcome in clinical trials.
We also investigated the extent to which the two tests were
correlated and compared their validity and responsiveness
(sensitivity to change).2. Methods
2.1. Study sample
The DARAD trial investigated the use of two antibiotics,
doxycycline and rifampicin, in 406 patients with mild to
moderate Alzheimer’s dementia. Subjects were randomized
into four arms: doxycycline 100 mg twice daily with rifam-
picin 300 mg daily, doxycycline 100 mg twice daily with
placebo rifampicin daily, rifampicin 300 mg daily with pla-
cebo doxycycline twice daily, or placebo doxycycline twice
daily with placebo rifampicin daily [17]. Patients were re-
cruited from 14 Canadian geriatric clinics between 2006
and 2010. The DARAD database contains data for a range
of variables at 1, 3, 6, 9, and 12 months. Patients aged
50 years or more, meeting the National Institute of Neuro-
logical Disorders and Stroke (NINCDS) criteria for Alz-
heimer’s disease [6], and with SMMSE scores between
14 and 26 were included. Patients were excluded if they
were unable to communicate verbally in English.
2.2. Measures
The coprimary outcomes in the DARAD trial were the
SADAS-cog and the Clinical Dementia Rating scale (CDR)
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89R. O’Caoimh et al. / Journal of Clinical Epidemiology 67 (2014) 87e92using the sum of the boxes technique [18,19]. Secondary out-
comes included the Qmci and the LawtoneBrody activities
of daily living (ADL) scale [20]. The LawtoneBrody scale
measures both basic (Physical Self-Maintenance Scale) and
instrumental (Lawton IADL scale) ADLs and has excellent
interrater reliability [21]. The SADAS-cog, Qmci, and
CDR were administered by a trained rater, in a random se-
quence, blinded to each study arm.
2.3. Data analysis
Data from the DARAD database were analyzed using
SPSS, version 18 (SPSS, Chicago, IL, USA) [22]. The
ShapiroeWilk test was used to test normality and found
that most data were approximately symmetrical, having
a small deviation from normality. The median and inter-
quartile range (IQR) were reported for skewed continuous
data (age and SMMSE). This analysis included only those
patients who had complete data. The correlations between
the Qmci and the SADAS-cog were calculated using the
data collected at 1, 3, 6, 9, and 12 months. The original
values were standardized to remove within-subject varia-
tions, and simple regression analyses were run to estimate
correlation coefficients. To address the validity of the two
instruments, the relationship between both the SADAS-
cog and the Qmci and two other variables (ADL and
CDR) were analyzed using different analytical ap-
proaches. Correlations were analyzed at each time point,
then for all time points together, and finally for mean
values across time. Fisher’s Z test was used to determine
differences in correlations between tests.
To compare the responsiveness of the two instruments,
at each time point, the standardized response mean
(SRM), the mean score change divided by the standard de-
viation (SD) of the score change using baseline as the ini-
tial score, were calculated for the SADAS-cog and Qmci.
Paired-samples t tests were performed to detect if a statisti-
cally significant difference existed in the SRM between the
SADAS-cog and Qmci.Ta
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.3. Results
Overall, 365 of the 406 patients who entered the DARAD
study completed 1 year [17]. Median age of the total popula-
tion was 79 years, IQR 10.Median SMMSE score at baseline
was 23, IQR 5. More than 90% were taking a cholinesterase
inhibitor and 13%, theN-Methyl-D-aspartate receptor antag-
onist, memantine. Three hundred sixty patients had complete
data for the Qmci and 363 for the SADAS-cog, 364 for the
ADL screen, and 360 for the CDR. Three hundred fifty-
eight patients had complete data for the Qmci and SADAS-
cog, at each time point, over the year.
Correlation coefficients between the outcome measures
along with their confidence intervals (CIs), at each time
point, at all time points, and using mean values across time
90 R. O’Caoimh et al. / Journal of Clinical Epidemiology 67 (2014) 87e92are reported in Table 1. The correlation coefficients demon-
strated significant strong correlation between the Qmci and
the SADAS-cog, at each time point (r 5 0.69; 95% CI:
0.62, 0.78; P  0.001 for the first month and 0.76;
95% CI: 0.70; 0.83; P  0.001 for the last month).
The data most closely correlated at 9 months (r 5 0.78;
P  0.001). Each patient was included five times (corre-
sponding to each time point) in the calculation, which
would be expected to inflate the value of the correlation co-
efficient. However, estimating correlations between mea-
sures overall, at all time points, pooled together, showed
that the correlations between the SADAS-cog and Qmci re-
mained strong and significant (r 5 0.75; 95% CI: 0.72,
0.78; P  0.001). Correlations increased to 0.8 using
mean values across time.
The relationship between the SADAS-cog and Qmci and
the other measures, ADL and CDR, at each of the five time
points, showed modest to strong significant correlations.
Correlations between the CDR and SADAS-cog (range
from 0.41 to 0.59) were stronger than those between the
ADL and SADAS-cog (range from 0.31 to 0.49).
Fig. 1 provides the correlations between the SADAS-cog
and Qmci and between the Qmci and SADAS-cog and the
other variables, ADL and CDR, at each time point. CIs
for correlations between the outcome measures at different
time points overlap, indicating no difference between them.
Fisher’s Z test confirmed that there was no statistically sig-
nificant difference in correlations between the SADAS-cog
and Qmci with either ADL (z 5 1.67; P 5 0.09) or CDR
scores (z 5 0.28; P 5 0.78). The correlation between
the SADAS-cog and itself (Table 2A), across time points,
varied from 0.79 to 0.91, higher than the correlationsFig. 1. Scatter plot depicting correlations between (A) SADAS-cog and Qm
scale, and (C) SADAS-cog and CDR, at each time point (1, 3, 6, 9, and 12
Scaleecognitive section; Qmci, Quick Mild Cognitive Impairment; CDR, Clibetween the SADAS-cog and the Qmci, which ranged
between 0.73 and 0.83 (Table 2B).
Responsiveness of the SADAS-cog and Qmci, deter-
mined using the SRM, demonstrated that the mean change
in SADAS-cog scores, between months 1 and 12, calcu-
lated for each patient, was 5 points, with an SD of 7.56.
The estimated mean difference in scores, repeated for the
Qmci, was 5.41 points, SD of 10.02. Paired-samples t test
showed that there was no statistically significant difference
in the SRMs for SADAS-cog and Qmci [t(357) 5 0.32,
P 5 0.75]. This means that the changes in Qmci scores
are very similar to changes in SADAS-cog scores, between
months 1 to 12.
There was a statistically significant increase in SADAS-
cog scores from a mean of 21.56, SD of 7.89 at month 1, to
a mean of 26.56, SD of 12.01 at month 12 [t(362) 5 12.60,
P ! 0.001]. There was also a statistically significant de-
crease in Qmci scores from month 1 (mean 5 38.58,
SD 5 12.83) to month 12 (mean 5 32.76, SD 5 15.593;
t(359) 5 10.23, P ! 0.001).4. Discussion
This study compared the SADAS-cog with the Qmci,
ADL, and CDR, by comparing observations at multiple
time points, from data collected in the DARAD trial, over
1 year. The SADAS-cog correlated closely with the Qmci,
irrespective of the method of analysis. Although individual
values of the Qmci corresponded to a relatively wide range
of values on the SADAS-cog, high correlation between the
two tests (0.69e0.76) demonstrates that the informationci, (B) SADAS-cog and LawtoneBrody activities of daily living (ADL)
months). SADAS-cog, Standardized Alzheimer’s Disease Assessment
nical Dementia Rating.
Table 2. Correlation of (A) the SADAS-cog to itself and (B) the Qmci to
itself, over each time point (1, 3, 6, 9, and 12 months)
A (1) (2) (3) (4)
(1) SADAS-cog at 1 mo d
(2) SADAS-cog at 3 mo 0.86a d
(3) SADAS-cog at 6 mo 0.86a 0.89a d
(4) SADAS-cog at 9 mo 0.83a 0.88a 0.90a d
(5) SADAS-cog at 12 mo 0.79a 0.84a 0.87a 0.91a
B (1) (2) (3) (4)
(1) Qmci at 1 mo d
(2) Qmci at 3 mo 0.80a d
(3) Qmci at 6 mo 0.79a 0.83a d
(4) Qmci at 9 mo 0.77a 0.81a 0.83a d
(5) Qmci at 12 mo 0.73a 0.76a 0.78a 0.82a
Abbreviations: SADAS-cog, Standardized Alzheimer’s Disease As-
sessment Scaleecognitive section; Qmci, Quick Mild Cognitive Im-
pairment screen.
a Correlation is significant at the 0.001 level.
91R. O’Caoimh et al. / Journal of Clinical Epidemiology 67 (2014) 87e92obtained is sufficiently similar to justify substitution of the
Qmci. Although the ratio of the mean change in Qmci
scores between the first and final visits (5.41) to the SD
of the change (10.02dratio 0.54) is smaller than that for
the SADAS-cog (5.0 and 7.56dratio 0.68), both differ-
ences were significant at values of !0.001, and the appar-
ent differences in SRMs are easily explained by chance
(P 5 0.75), suggesting that the Qmci and the SADAS-
cog are equally sensitive to change and have similar
responsiveness.
The SADAS-cog and Qmci also correlated with the ADL
and CDR. The CI for correlation coefficient estimates for
the Qmci and SADAS-cog and CI for correlations between
the SADAS-cog and ADL or CDR did not overlap, indicat-
ing a significantly stronger relationship between the Qmci
and SADAS-cog than between the ADL or CDR and
SADAS-cog and Qmci scores. In other words, the Qmci
and SADAS-cog are better predictors of each other than
of the other two measures (ADL and CDR). This is ex-
pected given that the SADAS-cog and Qmci are discrete
measures of cognitive function, which are distinct from
ADLs [23]. Therefore, the magnitude of change in func-
tional measures cannot be inferred from tests of cognitive
function and requires direct measurement. This suggests
that in addition to the use of cognitive testing, clinical trials
in dementia should incorporate measures of ADLs.
The strength of this article lies in its methodology. Cor-
relation between the SADAS-cog and each of the measures
was demonstrated using different statistical methods. Each
consistently confirmed strong correlation between the
SADAS-cog and Qmci and moderate-to-strong correlation
between the SADAS-cog and Qmci, ADL and CDR. The
correlations demonstrated at each of the five time points
were similar to the pooled correlation coefficients. Another
strength, is that these data, a post hoc analysis of the DAR-
AD trial database, represent the ‘‘real life’’ performance of
the Qmci, compared with the accepted standard, in a previ-
ously conducted, multicenter, blinded, randomizedcontrolled trial. Given that a four-point change, at 6 months,
in the ADAS or SADAS-cog is widely recognized as a clin-
ically significant difference [7,8], the similar responsive-
ness of the Qmci and SADAS-cog suggests that
a comparable change in the Qmci is equivalent to a signifi-
cant change in the SADAS-cog. Given that the Qmci is
shorter and easier to score, these data support the use of
the Qmci as an alternative to the SADAS-cog in clinical
trials.
This article has several limitations. Although a four-
point change in the SADAS-cog is traditionally accepted
as significant, it is not an ideal test. Comparing the Qmci
with the SADAS-cog only suggests that the Qmci has sim-
ilar sensitivity and responsiveness, not that it is a ‘‘gold
standard.’’ Although useful, the Qmci is less comprehensive
than the SADAS-cog and not all neuropsychological do-
mains are accounted for. That said, in contrast to the
SADAS-cog, the Qmci is shorter and easier to apply, cover-
ing many relevant cognitive domains including orientation,
working memory, visuospatial, executive function, se-
mantic memory, and episodic memory. In contrast, the
SADAS-cog is overly long and heavily weighted toward
language. The SADAS-cog, because of ceiling effects, is
less responsive to detecting MCI [24], possibly limiting
its usefulness. The Qmci, in contrast, is accurate at differen-
tiating MCI from NC and dementia [12], suggesting that
where this is the outcome measure of interest, the Qmci
could be used in preference. Although the SADAS-cog
requires substantial training [9], the Qmci, particularly the
clock drawing subtest, also requires training. Explicit
scoring and administration guidelines, including a clock-
scoring template, are available to improve reliability. That
said, clock drawing is a widely used screen for cognitive
impairment [25], different scoring methods are consistent
[26], and there is similar interrater reliability between
trained and untrained raters [27]. It is also regarded as be-
ing the easiest and quickest stand-alone cognitive screen
[25]. The ADL measure used in this study, the Lawtone
Brody scale, has limitations. Although it has excellent
interrater reliability [21] and measures both basic and
instrumental ADLs, like most ADL measures it is self-
reported, potentially over or underestimating functional im-
pairment and is not a gold standard for measuring ADLs.
In summary, the ADAS-cog and its standardized form,
the SADAS-cog, are valid, reliable, and widely used cogni-
tive measures in clinical trials [17,20,28,29]. They have
been validated internationally from Iceland [30] to Turkey
[31] and Hong Kong [32] and despite flaws, remain the
standard. These data demonstrate that the Qmci correlates
strongly, significantly, and correspondingly over time to
the SADAS-cog and that both are equally sensitive with
similar responsiveness to deterioration over time. Although
the correlation with each other was stronger, the SADAS-
cog and Qmci had moderate to strong correlations with both
functional (LawtoneBrody scale) and global assessments
(CDR), confirming their utility in clinical practice and drug
92 R. O’Caoimh et al. / Journal of Clinical Epidemiology 67 (2014) 87e92trials. Although further validation will be required, this
study provides a rationale for using the shorter Qmci, as
a cognitive outcome measure in clinical drug trials, partic-
ularly where differentiating MCI from NC and dementia is
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